These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 29769296)

  • 1. Interpreting risk reduction in clinical trials for pulmonary arterial hypertension.
    Lajoie AC; Bonnet S; Lacasse Y; Lega JC; Provencher S
    Eur Respir Rev; 2018 Jun; 27(148):. PubMed ID: 29769296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Building the case for novel clinical trials in pulmonary arterial hypertension.
    Ryan JJ; Rich JD; Maron BA
    Circ Cardiovasc Qual Outcomes; 2015 Jan; 8(1):114-23. PubMed ID: 25604559
    [No Abstract]   [Full Text] [Related]  

  • 3. Future perspectives in pulmonary arterial hypertension.
    Simonneau G; Hoeper MM; McLaughlin V; Rubin L; Galiè N
    Eur Respir Rev; 2016 Dec; 25(142):381-389. PubMed ID: 27903660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treat-to-target approach in pulmonary arterial hypertension: a consensus-based proposal.
    Sitbon O; Baloira Villar A; Bauer F; Ekmehag B; Gin-Sing W; Jansson K; Kiely DG; Leuchte H; Manes A; Rosenkranz S; Escribano P
    Eur Respir Rev; 2012 Sep; 21(125):259-62. PubMed ID: 22941892
    [No Abstract]   [Full Text] [Related]  

  • 5. Pulmonary Arterial Hypertension in Women.
    Memon HA; Park MH
    Methodist Debakey Cardiovasc J; 2017; 13(4):224-237. PubMed ID: 29744015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A paradigm shift in pulmonary arterial hypertension management.
    Rubin LJ; Galiè N; Simonneau G; McLaughlin V
    Eur Respir Rev; 2013 Dec; 22(130):423-6. PubMed ID: 24293459
    [No Abstract]   [Full Text] [Related]  

  • 7. Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?
    Correale M; Ferraretti A; Monaco I; Grazioli D; Di Biase M; Brunetti ND
    Vasc Health Risk Manag; 2018; 14():253-264. PubMed ID: 30323613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary arterial hypertension: tailoring treatment to risk in the current era.
    Gaine S; McLaughlin V
    Eur Respir Rev; 2017 Dec; 26(146):. PubMed ID: 29263175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond a single pathway: combination therapy in pulmonary arterial hypertension.
    Sitbon O; Gaine S
    Eur Respir Rev; 2016 Dec; 25(142):408-417. PubMed ID: 27903663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary hypertension-"state of the art" management in 2012.
    Saxena A
    Indian Heart J; 2012; 64(1):60-73. PubMed ID: 22572428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical considerations for therapies targeting the prostacyclin pathway.
    Farber HW; Gin-Sing W
    Eur Respir Rev; 2016 Dec; 25(142):418-430. PubMed ID: 27903664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macitentan for the treatment of pulmonary arterial hypertension.
    Spikes L; Williamson T; Satterwhite L
    Drugs Today (Barc); 2014 Jun; 50(6):401-6. PubMed ID: 24983588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early combination of pulmonary vasodilators prevents chronic kidney disease progression in connective tissue disease-associated pulmonary hypertension.
    Hanaoka H; Ishigaki S; Takei H; Hiramoto K; Saito S; Kondo Y; Kikuchi J; Kaneko Y; Takeuchi T
    Int J Rheum Dis; 2021 Nov; 24(11):1419-1426. PubMed ID: 34626090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience.
    Sitbon O; Vonk Noordegraaf A
    Eur Respir Rev; 2017 Jan; 26(143):. PubMed ID: 28096285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and treatment of pulmonary hypertension.
    Haeck ML; Vliegen HW
    Heart; 2015 Feb; 101(4):311-9. PubMed ID: 24855320
    [No Abstract]   [Full Text] [Related]  

  • 16. Number needed to treat is incorrect without proper time-related considerations.
    Suissa D; Brassard P; Smiechowski B; Suissa S
    J Clin Epidemiol; 2012 Jan; 65(1):42-6. PubMed ID: 21816576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of randomized controlled trials of bosentan for treatment of pulmonary arterial hypertension.
    Lee YH; Song GG
    Korean J Intern Med; 2013 Nov; 28(6):701-7. PubMed ID: 24307846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension.
    Udeoji DU; Schwarz ER
    Ther Adv Respir Dis; 2013 Feb; 7(1):39-49. PubMed ID: 23129569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New horizons in pulmonary arterial hypertension therapies.
    Galiè N; Ghofrani AH
    Eur Respir Rev; 2013 Dec; 22(130):503-14. PubMed ID: 24293466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic post-embolic pulmonary hypertension: a new target for medical therapies?
    Delcroix M
    Eur Respir Rev; 2013 Sep; 22(129):258-64. PubMed ID: 23997053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.